The concentration and persistence of health care expenditures and prescription drug expenditures in medicare beneficiaries with alzheimer disease and related dementias

Medical Care

Volumn 47, Issue 11, 2009, Pages 1174-1179

  Lin, Pei Jung ^a   Biddle, Andrea K ^b   Ganguly, Rahul ^c   Kaufer, Daniel I ^d   MacIejewski, Matthew L ^e,f  

^a TUFTS MEDICAL CENTER   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Drug expenditures; Health expenditures; High cost illness; Medicare

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DEMENTIA; DRUG COST; HEALTH CARE COST; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; MEDICARE; PHYSICIAN; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COHORT STUDIES; DEMENTIA; FEMALE; HEALTH EXPENDITURES; HEALTH STATUS; HUMANS; MALE; PRESCRIPTION DRUGS; PRESCRIPTION FEES; RETROSPECTIVE STUDIES;

EID: 70350554265     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181b69fc1     Document Type: Article

References (31)

1. Riley GF. Long-term trends in the concentration of Medicare spending. Health Aff (Millwood). 2007;26:808-816.
2. Garber AM, MaCurdy TE, McClellan MC. Persistence of medicare expenditures among elderly beneficiaries. 1997. Available at: http:// www.nber.org/papers/ w6249. Accessed December 12, 2006.
3. Banthin JS, Miller E. Persistence in Medicare Prescription Drug Expenditures by Treatment Class. Agency for Healthcare Research and Quality Working Paper No. 06006. 2006. Available at: http://gold.ahrq.gov. Accessed September 15, 2007.
4. Coulson NE, Stuart B. Persistence in the use of pharmaceuticals by the elderly. Evidence from annual claims. J Health Econ. 1992;11:315-328.
5. Wrobel MV, Doshi J, Stuart BC, et al. Predictability of prescription drug expenditures for Medicare beneficiaries. Health Care Financ Rev. 2003; 25:37-46.
6. Ash AS, Zhao Y, Ellis RP, et al. Finding future high-cost cases: comparing prior cost versus diagnosis-based methods. Health Serv Res. 2001;36:194-206
7. California Workgroup on Guidelines for Alzheimer's Disease Management. Guideline for Alzheimer's Disease Management. Chicago, IL: Alzheimer's Association 2008.
8. CMS. Survey overview 2006. Available at http://www.cms.hhs.gov/ apps/mcbs/Overview.asp. Accessed November 1, 2006.
9. Hill JW, Futterman R, Duttagupta S, et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58:62-70.
10. Gutterman EM, Markowitz JS, Lewis B, et al. Cost of Alzheimer's disease and related dementia in managed-Medicare. J Am Geriatr Soc. 1999;47:1065-1071.
11. Hill J, Fillit H, Thomas SK, et al. Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias. Pharmacoeconomics. 2006;24:265-280.
12. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
13. Alzheimer's Association. Alzheimer's Disease Facts and Figures. Chicago, IL: Alzheimer's Association; 2009.
14. England A, Hubbell K, Judkins D, et al. Imputation of medical cost and payment data. Proceedings of the Section on Survey Research Methods. Toronto, Canada: American Statistical Association; 1994:406-411
15. Bureau of Labor Statistics. Consumer price index 2007. Available at http://www.bls.gov/cpi/home.htm. Accessed September 15, 2007.
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
18. Kuo TC, Zhao Y, Weir S, et al. Implications of comorbidity on costs for patients with Alzheimer disease. Med Care. 2008;46:839-846.
19. Zuvekas SH, Cohen JW. Prescription drugs and the changing concentration of health care expenditures. Health Aff (Millwood). 2007;26:249-257.
20. Berk ML, Monheit AC. The concentration of health care expenditures, revisited. Health Aff (Millwood). 2001;20:9-18.
21. Cohen SB, Ezzati-Rice T, Yu W. The utility of extended longitudinal profiles in predicting future health care expenditures. Med Care. 2006; 44:I45-I53.
22. Shen Y, Ellis RP. How profitable is risk selection? A comparison of four risk adjustment models. Health Econ. 2002;11:165-174.
23. Maciejewski ML, Dowd B, O'Connor H. Multiple prior years of health expenditures and Medicare health plan choice. Int J Health Care Finance Econ. 2004;4:247-261
24. CMS. SNP Comprehensive Report. 2008. Available at: http://www.cms.hhs. gov/MCRAdvPartDEnrolData/SNP/list.asp#TopOfPage. Accessed November 1, 2008.
25. Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam Med. 2002;34:528-535.
26. Kaufer DI, Borson S, Kershaw P, et al. Reduction of caregiver burden in Alzheimer's disease by treatment with galantamine. CNS Spectr. 2005; 10:481-488
27. First SNP for Alzheimer's disease implemented. Dis Manag Advis. 2008;14(suppl 1-2):1.
28. Peikes D, Chen A, Schore J, et al. Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries: 15 randomized trials. JAMA. 2009;301:603-618.
29. Newcomer R, Clay T, Luxenberg JS, et al. Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records. J Am Geriatr Soc. 1999;47:215-219.
30. Pressley JC, Trott C, Tang M, et al. Dementia in community-dwelling elderly patients: a comparison of survey data, Medicare claims, cognitive screening, reported symptoms, and activity limitations. J Clin Epidemiol. 2003;56:896-905.
31. Lin PJ, Kaufer DI, Meciejewski ML, et al. An examination of alzheimer's case definitions using medicare claims and survey data. (working paper). 2009